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Abstract Migraine is a common brain disorder with high
disability rates which involves a series of abnormal neu-
ronal networks, interacting at different levels of the central
and peripheral nervous system. An increase in the interest
around migraine pathophysiology has allowed researchers
to unravel certain neurophysiological mechanisms and
neurotransmitter involvement culminating in the recent
development of novel therapies, which might substantially
change the clinical approach to migraine patients. The
present review will highlight the current aspects of
migraine pathophysiology, covering an understanding of
the complex workings of the migraine state and the brain
regions responsible for them. We will further discuss the
therapeutic agents which have appeared in the most recent
years for migraine care, from calcitonin gene-related pep-
tide (CGRP) receptor antagonists, gepants; through sero-
tonin 5-HT1F receptor agonists, ditans, and CGRP or
CGRP receptor monoclonal antibodies to invasive and non-
invasive neuromodulation techniques.
Keywords Migraine  Pathophysiology  Treatment 
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Introduction
Migraine is the most common neurological cause of dis-
ability in the world [1]. Notwithstanding, clinicians and
researchers have seen little progress in the therapeutic
options available to treat this condition in the last two
decades. Recent advances in our understanding of migraine
pathophysiology have allowed the development of phar-
macological and non-pharmacological treatments that offer
the advantage of targeting mechanisms known to be active
in the disorder leading to better management of patients.
The current review follows this bench to bedside
approach [2], with an outline of relevant mechanisms in
migraine biology, followed by an up-to-date summary of
the most important therapies used in migraine at the present
stage.
Migraine pathophysiology
Over the last two decades our knowledge of the biology of
migraine has improved considerably, with a series of basic
science and imaging studies that demonstrate how vascular
changes, first thought to explain migrainous pain, are nei-
ther necessary, nor sufficient in migraine [3, 4]. From a
vascular theory the field has moved on to Neuronal theories
involving the central or peripheral nervous system, or both.
Much research has focused on specific brain structures
thought to be at the basis of pain, arguably the primary
migraine symptom. With these advances, it has become
clear that the concept of a unique migraine generator may
not be useful, in view of the variety of overlapping phases
that constitute the migraine attack.
It is now widely accepted that migraine should be
viewed as a complex brain network disorder with a strong
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genetic basis that involves multiple cortical, subcortical
and brainstem regions to account for the pain and the wide
constellation of symptoms characterizing the attack [4–6].
Here we will describe some important advances in our
understanding of the different brain areas known to be
directly involved in the premonitory, aura, pain and post-
dromal phases of migraine.
The trigeminal vascular system and brainstem
nuclei
The trigeminovascular system is one of the key actors in
the expression of migraine headache. It consists of
peripheral axons from the trigeminal ganglion that reach
the meninges and intracranial arteries and converge cen-
trally in the trigeminocervical complex releasing, among
other transmitters, calcitonin gene-related peptide (CGRP)
[7, 8]. The trigeminocervical complex (TCC) consists of
the trigeminal nucleus caudalis along with the dorsal horn
of C1–C2 segments of the spinal cord [9, 10]. Its acti-
vation is thought to lead to the cascade of events resulting
in the migraine pain due to its direct connection with key
brain centres such as diencephalic and brainstem nuclei
[11, 12].
In the late 1980s it was proposed that migraine pain may
be due to a sterile neurogenically induced inflammation of
the dura mater [13, 14]. However, the failure of specific
plasma protein extravasation blockers as acute or preven-
tive migraine treatments in randomized controlled trials
suggested other explanations were needed [15, 16]. Human
observational [17] and brain imaging studies [18–20] have
suggested a role of brainstem regions, such as the peri-
aqueductal grey matter (PAG) and the dorsolateral pons
(DLP), in migraine attacks: the ‘migraine generator’. In
addition, a series of laboratory experiments have proposed
that the brainstem might act as a driver of changes in
cortical activity during migraine [21, 22]. Although the
validity of the brainstem generator theory has been widely
debated in the last few years [23], the role of relevant
brainstem nuclei—including the rostral ventral medulla,
the locus coeruleus, the superior salivatory and cuneiform
nucleus—in modulating trigeminovascular pain transmis-
sion and autonomic responses in migraine is well estab-
lished [4, 18, 19]. Furthermore, there is evidence showing
antimigraine drugs such as triptans [24, 25], ergot deriva-
tives [26, 27] and the novel CGRP receptor antagonists
[28, 29] can specifically modulate activity in the TCC,
which might explain their effect in aborting migraine.
The hypothalamus
The central role of the hypothalamus in cluster headache
and other trigeminal autonomic cephalalgias is well
established [30–32]. Several studies have recently
highlighted its possible involvement in migraine as well.
Evidence shows that this brain structure has direct and
indirect anatomical connections to the thalamus [33],
trigeminovascular neurons [34, 35] and sympathetic and
parasympathetic brainstem nuclei [36], supporting its
role in nociceptive and autonomic modulation in
migraine patients. Previous positron emission tomogra-
phy studies have shown hypothalamic activation during
spontaneous migraine headache [37] and during the
premonitory phase [38]. Recently, Schulte and May
performed an elegant study in which a migraine patient
underwent functional neuroimaging for 30 consecutive
days. During the 24 h preceding the attack as well as
throughout the ictal phase an altered functional con-
nectivity between the hypothalamus and the areas of the
brainstem generator was found, leading the authors to
hypothesize that this network change might be the real
driver of attacks [39]. The key involvement of the
hypothalamus in migraine explains symptoms that begin
in the early ictal stages and last throughout the attack,
such as craving, mood changes, yawning and fatigue
[4, 40].
The thalamus
The thalamus is a nociceptive relay station where inputs
from the dura mater as well as cutaneous regions are
conveyed through second-order trigeminovascular neurons.
It is a central area for the processing and integration of pain
stimuli and its connection to a wide variety of cortical areas
such as the somatosensory, motor, visual, auditory, olfac-
tory and limbic regions can explain part of the complexity
of migraine features [41]. Thalamo-cortical transmission is
constantly modulated by different pathways involved in
cognition, emotion and autonomic responses [42]. Several
studies have reported structural [43–45] and functional
[19, 46–49] thalamic alterations in migraineurs during the
ictal and interictal phase, which can be detected since the
paediatric age and might influence the onset of the
migraine attack. Furthermore, the thalamus has shown to
be a pivotal area for the development of sensory hyper-
sensitivity to visual stimuli [50] and mechanical allodynia
[51].
Several acute [24] and preventive [52–55] migraine
therapies are thought to act centrally through the modula-
tion of thalamic neurons. Recently, Andreou et al. [56]
showed that the efficacy of single pulse transcranial mag-
netic stimulation (sTMS) in the treatment of migraine with
and without aura [57] might be related not only to its
capability to block cortical spreading depression (CSD) but




Even if the role of the cortical wave of spreading depres-
sion first identified by Lea˜o [58, 59] in the generation of
aura is well established [60, 61], its activity as a potential
trigger for migraine headache is less clear. Those in favour
of this theory argue that experimental studies in rats have
shown that CSD can trigger neurogenic meningeal
inflammation and subsequently activate the trigeminovas-
cular system [62, 63]; however, this has not been confirmed
in humans. Many changes in the structure and function of
key cortical areas have been reported over the last years in
migraine patients both with and without aura. Specifically,
cortical changes in the ictal and interictal period have been
shown in regions normally associated with pain processing
such as the insular, somatosensory, prefrontal, and cingu-
late cortex [64, 65].
A large body of evidence has pointed to an increased
sensitivity to different sensory stimuli in migraineurs dur-
ing the attack and in the interictal phase [66]. In addition,
several neurophysiological studies have reported a reduc-
tion of the common physiological response known as
habituation, in which repeated stimulations cause a decre-
ment in the amplitudes of sensory responses [67, 68]. The
lack of habituation in migraine, measured for different
sensory modalities, usually occurs during the pain-free
period and reverts during the ictal phase or with attacks
becoming more frequent [66]. Although the neural mech-
anisms underlying sensitization and habituation deficits
remain poorly understood, the presence of a widespread
cortical dyshabituation has been hypothesized as one of the
main contributors to this deficit [69].
Recent large genome-wide association studies have
identified 13 susceptibility gene variants in migraine
patients which are mainly involved in glutamatergic neu-
rotransmission and synaptic plasticity, and whose impair-
ment may, therefore, be considered a key mechanism
underlying an abnormal cortical excitability [70, 71].
Finally, positive results from the use of novel thera-
peutic approaches capable of modulating neuronal activity
in the cortex also confirm the possibility of an abnormal
cortical responsivity in migraine [56], as will be high-
lighted further.
Novel therapies in migraine
Migraine therapy has historically been divided between
acute and preventive treatments, a structure that for sim-
plicity is followed in this review. It is, however, becoming
evident that this dichotomous principle might in fact be
dated [2], especially by observing the mechanism of action
of novel migraine therapies such as the CGRP antagonists,
which have been studied as both acute and preventive
migraine agents.
Acute therapies
Treatment for the acute migraine attack ranges from non-
specific medications—such as non-steroidal anti-inflam-
matory drugs and combination analgesics—to migraine-
specific drugs, including ergotamine preparations and
triptans. Triptans, which act by targeting 5-HT1B and
5-HT1D serotonin receptors, were the first drugs specifi-
cally developed as acute migraine therapies [72]. Although
they can be very effective in many individuals, they often
have significant limitations to their use caused by adverse
effects. Furthermore, lack of efficacy and recurrence of
migraine symptoms are seen in over 50% of cases in most
studies [73, 74]. As a consequence, in the last years there
has been a search for promising novel therapeutic agents to
better treat migraine patients.
CGRP is a neuropeptide widely expressed in both
peripheral and central neurons. Aside from its action as a
potent cerebral arteriolar dilatator, substantial evidence has
pointed to its role in modulating central and peripheral pain
circuits. Studies showing the mediating action of CGRP on
second- and third-order neurons seem to underline its
regulatory role in central pain mechanisms. Furthermore,
elevation of this molecule in migraineurs is thought to be
linked to a decrease in descending inhibitory mechanisms
which in turn might lead to migraine susceptibility through
sensitization of multiple central neuronal circuits [8].
These findings have progressively led to the development
of new drugs that target the CGRP pathway. Six different
CGRP receptor antagonists, the gepants, have been devel-
oped for use in acute migraine [72]. Remarkably, each
study reported positive outcomes on the primary endpoint
of pain freedom when comparing the new drugs to placebo.
However, two studies were stopped due to liver toxicity
[75, 76] and three because of lack of interest from the
companies [77–79]. One study testing the molecule ubro-
gepant is currently in phase III [80]. Notably, these
medicines have a better tolerability in terms of central
nervous system and vascular side effects compared to
triptans and they seem to present a lower risk of causing
medication overuse [2, 73].
Another encouraging new acute treatment for migraine
is represented by the drug class of 5-HT1F receptor agonist
called ditans. Several studies have shown that 5-HT1F
receptors are not expressed in the vasculature [81] and that
ditans inhibit activation of cells in the trigeminal nucleus
caudalis evoked by trigeminal stimulation [82, 83]. Las-
miditan has been studied in two randomized, placebo-
controlled double-blind trials which showed significant
improvement, measured in terms of headache freedom at
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2 h [84, 85], with its use. The main advantage of this new
drug is the lack of any cardiovascular and cerebrovascular
effects [86], although mild side effects such as dizziness,
fatigue, vertigo and somnolence have been reported in the
randomized controlled trials (RCT).
Glutamatergic targets, including both metabotropic and
ionotropic glutamate receptors, are also expected to have a
prominent role in future migraine therapy. Recent experi-
mental and clinical studies have shown an effect of
NMDA, AMPA, iGluR5 and mGluR5 receptor antagonists
in migraine, although their efficacy was lower than that of
sumatriptan and related visual side effects were observed
[87–89]. The NMDA receptor, however, could prove to be
an important target for the management of migraine with
aura, as shown by small RCT testing the effects of keta-
mine in reducing the severity of auras [90].
Preventive therapies
Preventive therapies are recommended in patients with
chronic migraine and in more than a third of episodic
migraine patients, especially in the case of frequent attacks
or in subjects who do not tolerate and respond to acute
treatments [91]. Many drugs of different pharmacological
categories—such as b blockers, anticonvulsants, tricyclic
antidepressants and calcium channel modulators—have
been approved for migraine prevention or have class A
evidence supporting their use. Patients’ compliance and
adherence to these medications, however, is often poor due
to their modest efficacy and adverse effects [86]. There-
fore, more effective and better tolerated drugs are currently
being studied for preventive use in migraine, mainly rep-
resented by monoclonal antibodies (mAB) to either CGRP
peptide (galcanezumab, eptinezumab or TEV-48125) or its
canonical receptor (erenumab). Data from a total of five
RCTs performed on episodic migraine patients [92–96]
revealed that these compounds present a therapeutic gain—
measured through 50% responder rates for migraine/prob-
able migraine days—ranging from 17 to 31. In the two
placebo-controlled RCTs for chronic migraine [97, 98] the
therapeutic gain was of 16 and 24 [2]. Even though mon-
oclonal antibodies are very likely to represent the future
strategy for effective migraine prevention, there are several
caveats to their use that need to be considered. First, given
the relatively short duration of the ongoing studies, evi-
dence is needed to exclude long-term issued linked to the
use of mAB. Furthermore, there is little knowledge
regarding the development of autoantibodies against these
compounds following prolonged treatment. Lastly, the
elevated cost of these molecules must be counterbalanced
by a high patient benefit to justify their extensive use.
Other targets for migraine therapy focusing on the
supposed pathophysiological role of neuroinflammation in
inducing migraine attacks—such as substance P, neu-
rokinin 1 receptors [99] and orexin receptors [100]—have
consistently failed in clinical trials in recent years. This
evidence once more suggests that targeted migraine ther-
apies must focus on specific neuronal mechanisms [2, 86].
Neuromodulation
Neuromodulation is a promising approach that has
emerged in recent years with both acute and preventive
migraine treatment strategies. These exciting techniques
range from invasive approaches such as occipital nerve
stimulation (ONS) and sphenopalatine ganglion (SPG)
stimulation, which have been used for several years and are
largely positioned in intractable chronic patients, to more
modern non-invasive devices that target the nervous sys-
tem transcutaneously. The latter are mainly represented by
TMS, non-invasive vagus nerve stimulation (nVNS),
supraorbital nerve stimulation and transcranial direct cur-
rent stimulation (tDCS).
ONS has been investigated as a prevention in chronic
migraine patients in three randomized controlled trials:
each was negative [101–103]. A later open-label follow-up
study has shown a modest 12-month efficacy rate of ONS
for headache pain and disability, although the complication
rates associated with this procedure were still high [104].
Several experimental studies have demonstrated that the
SPG has connections with the trigeminovascular system
[105], explaining the presence of cranial autonomic
symptoms in primary headaches and suggesting a potential
role for the SPG in pain modulation [106]. Preliminary
studies reported an improvement in pain intensity after
lidocaine-induced SPG block [107, 108] or electrical SPG
stimulation [109] during acute migraine attacks. In addi-
tion, a trend of reduction in migraine days per month and
an amelioration in several quality of life measures were
reported after repetitive SPG blockades with 0.5% bupi-
vacaine [110]. Two RCTs are currently evaluating the
acute use of a surgically implanted SPG neurostimulator in
high disability migraine (NCT01540799, NCT01294046)
and results are awaited. The positive results of a double-
blind, randomized, sham-controlled trial performed on 67
episodic migraine patients (the PREMICE study) [111]
followed by an audit on more than 2000 patients [112] have
led to the approval of the non-invasive transcutaneous
supraorbital nerve stimulator (Cefaly) as a preventive
treatment for migraine. A current RCT (NCT02590939) is
testing the Cefaly device as an acute treatment; however,
further studies with a focus on blinding issues are needed to
confirm its efficacy as a preventive treatment in migraine.
Early studies on patients with comorbid epilepsy or
depression and headache supported a possible effect of
vagus nerve stimulation in migraine. Different open-label
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studies for the treatment of acute migraine attacks using a
novel portable device for nVNS (GammaCore) demon-
strated that its effect was comparable to that of most
commonly used triptans with mild and well-tolerated side
effects [113–115]. Regarding its preventive use, a double-
blind, sham-controlled study in chronic migraine patients
revealed a modest reduction in headache days in the active
group compared to the sham group after two months (-1.4
vs. -0.2 days; p = 0.56) [116]. However, the open-label
extension data suggests that longer term use of nVNS
might be effective. Another recent open-label study on
menstrual-related migraine reported a significant reduction
in the number of migraine days and analgesic use following
a 12-week treatment period in 56 patients [117].
On the basis of previous experimental studies [118] and
recent evidence [56] supporting a positive effect of sTMS
in inhibiting CSD and the activity of thalamo-cortical
neurons, a handheld device (SpringTMS) has been
recently developed and approved for the treatment of acute
migraine attacks. A preliminary multicentre, randomized,
double-blind, parallel-group, sham-controlled study [57] on
164 migraine patients with aura demonstrated a superiority
of sTMS over sham stimulation for pain freedom at 2 h (39
vs 22%, p = 0.018) and for sustained pain freedom at 24
(29 vs 16%, p = 004) and 48 (27 vs 13%, p = 003)
hours. Moreover, a post-marketing phone-based survey
[119] on 190 episodic and chronic migraine patients
revealed that 62% had a reduction in their migraine
headaches and 59% reported a decrease in the number of
headache days after a 12-week treatment. There is, how-
ever, still a lack of large controlled RCTs to support the use
of the sTMS for the prevention of migraine.
Another neuromodulation approach has focused on the
application of repeated cathodal or anodal transcranial
direct current stimulation over the visual cortex, although
data on its therapeutic effect in migraineurs have been
conflicting [120, 121].
It is clear from the available evidence that although very
promising, neuromodulation techniques require further
studies to confirm their efficacy in migraine.
Conclusions
The recent recognition of migraine as a debilitating neu-
rological condition is an important advance in directing
more resources to the development of new treatments and
their deployment to patients. The last two decades have
seen a number of important studies in the area of primary
headaches leading to an extremely exciting era for
researchers interested in this disorder. New treatments are
rapidly becoming available for patients and a better
understanding of its pathophysiological mechanisms is
allowing a greater awareness of the complexity of a brain
disease which has often been overlooked and under-
managed.
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